NASDAQ:ALNYAlnylam Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $136.61 -1.96 (-1.41 %) (As of 08/12/2020 04:00 PM ET) Add Compare Share Today's Range$133.40Now: $136.61▼$139.9650-Day Range$138.57MA: $153.30▼$165.4952-Week Range$73.32Now: $136.61▼$167.33Volume469,900 shsAverage Volume781,351 shsMarket Capitalization$15.84 billionP/E RatioN/ADividend YieldN/ABeta1.81 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. It provides ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. The company's development programs include Vutrisiran, an investigational RNAi therapeutic targeting transthyretin that is in Phase III trials for the treatment of transthyretin-mediated amyloidosis; Givosiran that is in Phase III trials to treat acute hepatic porphyrias; and Lumasiran, an investigational RNAi therapeutic, which is in Phase III clinical trials for glycolate oxidase to treat primary hyperoxaluria type 1. It is also developing Inclisiran, an investigational RNAi therapeutic targeting proprotein convertase subtilisin/kexin type 9 that is in Phase III clinical trials for the treatment of hypercholesterolemia; and Fitusiran, an investigational RNAi therapeutic that is in Phase III clinical trials for treating hemophilia A and B with or without inhibitors. In addition, the company engages in the development of Cemdisiran for complement-mediated diseases; ALN-AAT02 to treat alpha-1 anti-trypsin deficiency-associated liver disease; ALN-HBV02 for treating chronic hepatitis B virus infection; and other earlier-stage programs. Alnylam Pharmaceuticals, Inc. has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Ionis Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingAlnylam Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.63, and is based on 13 buy ratings, 5 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $150.89, Alnylam Pharmaceuticals has a potential upside of 10.2% from its current price of $136.88.Amount of Analyst CoverageAlnylam Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.3 Community Rank Outperform VotesAlnylam Pharmaceuticals has received 993 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAlnylam Pharmaceuticals has received 508 “underperform” votes. (Add your “underperform” vote.)Community SentimentAlnylam Pharmaceuticals has received 66.16% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Alnylam Pharmaceuticals and other stocks. Vote “Outperform” if you believe ALNY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ALNY will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAlnylam Pharmaceuticals does not currently pay a dividend.Dividend GrowthAlnylam Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alnylam Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,941,874.00 in company stock.Percentage Held by InsidersOnly 3.50% of the stock of Alnylam Pharmaceuticals is held by insiders.Percentage Held by Institutions92.95% of the stock of Alnylam Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Alnylam Pharmaceuticals are expected to grow in the coming year, from ($6.84) to ($5.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alnylam Pharmaceuticals is -18.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alnylam Pharmaceuticals is -18.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlnylam Pharmaceuticals has a P/B Ratio of 11.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.65 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:ALNY Previous Symbol CUSIP02043Q10 CIK1178670 Webwww.alnylam.com Phone617-551-8200Debt Debt-to-Equity Ratio0.20 Current Ratio5.62 Quick Ratio4.48Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$219.75 million Price / Sales72.09 Cash FlowN/A Price / Cash FlowN/A Book Value$12.07 per share Price / Book11.32Profitability EPS (Most Recent Fiscal Year)($8.11) Net Income$-886,120,000.00 Net Margins-245.14% Return on Equity-58.40% Return on Assets-31.96%Miscellaneous Employees1,323 Outstanding Shares115,970,000Market Cap$15.84 billion Next Earnings Date10/29/2020 (Estimated) OptionableOptionable $136.61 -1.96 (-1.41 %) (As of 08/12/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ALNY News and Ratings via Email Sign-up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. Alnylam Pharmaceuticals (NASDAQ:ALNY) Frequently Asked Questions How has Alnylam Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)? Alnylam Pharmaceuticals' stock was trading at $101.89 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ALNY shares have increased by 34.1% and is now trading at $136.61. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Alnylam Pharmaceuticals? 19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 1 sell rating, 5 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Alnylam Pharmaceuticals. When is Alnylam Pharmaceuticals' next earnings date? Alnylam Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020. View our earnings forecast for Alnylam Pharmaceuticals. How were Alnylam Pharmaceuticals' earnings last quarter? Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) released its quarterly earnings data on Thursday, August, 6th. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($1.82) by $0.26. The biopharmaceutical company had revenue of $77.50 million for the quarter, compared to analysts' expectations of $98.76 million. Alnylam Pharmaceuticals had a negative return on equity of 58.40% and a negative net margin of 245.14%. Alnylam Pharmaceuticals's revenue for the quarter was up 102.9% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.83) EPS. View Alnylam Pharmaceuticals' earnings history. What price target have analysts set for ALNY? 19 analysts have issued 1-year price targets for Alnylam Pharmaceuticals' stock. Their forecasts range from $74.00 to $202.00. On average, they expect Alnylam Pharmaceuticals' stock price to reach $150.89 in the next twelve months. This suggests a possible upside of 10.5% from the stock's current price. View analysts' price targets for Alnylam Pharmaceuticals. Has Alnylam Pharmaceuticals been receiving favorable news coverage? Press coverage about ALNY stock has been trending somewhat negative this week, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Alnylam Pharmaceuticals earned a media sentiment score of -1.2 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about Alnylam Pharmaceuticals. Who are some of Alnylam Pharmaceuticals' key competitors? Some companies that are related to Alnylam Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU), Novavax (NVAX) and Repligen (RGEN). View all competitors. What other stocks do shareholders of Alnylam Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Gilead Sciences (GILD), Ionis Pharmaceuticals (IONS), NXP Semiconductors (NXPI), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), Mylan (MYL) and Advanced Micro Devices (AMD). Who are Alnylam Pharmaceuticals' key executives? Alnylam Pharmaceuticals' management team includes the following people: Dr. John M. Maraganore, CEO & Exec. Director (Age 56)Mr. Barry E. Greene, Pres (Age 56)Mr. Manmeet Singh Soni, Sr. VP, CFO & Principal Accounting Officer (Age 41)Dr. Yvonne Greenstreet MBChB, MBA, Exec. VP & COO (Age 56)Dr. Akshay K. Vaishnaw, Pres of R&D (Age 56) What is Alnylam Pharmaceuticals' stock symbol? Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY." Who are Alnylam Pharmaceuticals' major shareholders? Alnylam Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include First Trust Advisors LP (0.70%), Sumitomo Mitsui Trust Holdings Inc. (0.48%), Swiss National Bank (0.39%), Bank of New York Mellon Corp (0.37%), Rockefeller Capital Management L.P. (0.33%) and California Public Employees Retirement System (0.22%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, Barry E Greene, John Maraganore, Laurie Keating, Marsha Fanucci, Philip A Sharp, Phillip A Sharp, Steven M Paul and Yvonne Greenstreet. View institutional ownership trends for Alnylam Pharmaceuticals. Which institutional investors are selling Alnylam Pharmaceuticals stock? ALNY stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., First Trust Advisors LP, Frontier Capital Management Co. LLC, Candriam Luxembourg S.C.A., Amalgamated Bank, Rhenman & Partners Asset Management AB, UBS Group AG, and Peregrine Capital Management LLC. Company insiders that have sold Alnylam Pharmaceuticals company stock in the last year include Akshay Vaishnaw, Barry E Greene, John Maraganore, Laurie Keating, Marsha Fanucci, Phillip A Sharp, Steven M Paul, and Yvonne Greenstreet. View insider buying and selling activity for Alnylam Pharmaceuticals. Which institutional investors are buying Alnylam Pharmaceuticals stock? ALNY stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Robeco Institutional Asset Management B.V., Kornitzer Capital Management Inc. KS, Teacher Retirement System of Texas, SG Americas Securities LLC, California Public Employees Retirement System, Envestnet Asset Management Inc., and State of Alaska Department of Revenue. View insider buying and selling activity for Alnylam Pharmaceuticals. How do I buy shares of Alnylam Pharmaceuticals? Shares of ALNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Alnylam Pharmaceuticals' stock price today? One share of ALNY stock can currently be purchased for approximately $136.61. How big of a company is Alnylam Pharmaceuticals? Alnylam Pharmaceuticals has a market capitalization of $15.84 billion and generates $219.75 million in revenue each year. The biopharmaceutical company earns $-886,120,000.00 in net income (profit) each year or ($8.11) on an earnings per share basis. Alnylam Pharmaceuticals employs 1,323 workers across the globe. What is Alnylam Pharmaceuticals' official website? The official website for Alnylam Pharmaceuticals is www.alnylam.com. How can I contact Alnylam Pharmaceuticals? Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-551-8200 or via email at [email protected] This page was last updated on 8/12/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
